Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    FDA Approves Tapentadol for Relief of Moderate to Severe Acute Pain - (DGNews)
    Infection-Related Deaths Reported With Alemtuzumab, Warns Health Canada - (DGNews)
    Model Predicts Outcomes of Pegylated Interferon Therapy in Patients With Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Long-Term Erythromycin Therapy Reduces COPD Exacerbations, but Raises Concerns - (DGNews)
    FDA Approves Eltrombopag for the Treatment of Chronic Immune Thrombocytopenic Purpura - (DGNews)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Asthma Treatment Guidelines and Use of Inhalers
      Use of Probiotics in the Management of Antibiotic-associated Diarrhea
      Antiplatelet Agents in the Prevention of Atherothrombotic Events
      Limiting GERD Progression in Older Patients: Reducing Costs Through Optimal Management
      New Guidelines for the Diagnosis and Management of Asthma

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Is Enoxaparin Injection from the Abdominal Wall Safe in Elderly People?: A Fatal Case of Rectus Sheath Hematoma
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Massive Pulmonary Emboli Associated with Olanzapine
        Exacerbation of Hepatitis C Induced Subclinical Hypoadrenalism by Interferon-Alpha2beta: A Case Report
        Complete Clinical Response of Metastatic Hepatocellular Carcinoma to Sorafenib in a Patient with Hemochromatosis: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Long-Term Galantamine Therapy Safe, Effective for Dementia Patients

        A DGReview of :"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia"
        Clinical Therapeutics

        08/06/2003
        By Jill Taylor


        Galantamine produces long-term benefits and is well tolerated in patients with vascular dementia (VaD) and Alzheimer's disease (AD) with cerebrovascular disease (CVD), according to a new study.

        Primarily associated with the elderly, dementia is a growing concern as a large proportion of the population ages. While AD and VaD are the most common types of dementia, epidemiologic evidence suggests that many dementia patients have both AD and CVD, otherwise known as mixed dementia.

        Because cholinergic dysfunction is involved in both AD and mixed dementia, use of acetylcholinesterase (AChE) inhibitors in the treatment of dementia is a developing area of research. Galantamine, an AChE inhibitor and allosteric nicotinic modulator, has shown broad clinical benefit in mild to moderate dementia cases.

        In an open-label extension of a 6-month double-blind study of galantamine, Timo Erkinjuntti, MD, of the Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland, and colleagues evaluated the long-term efficacy and safety profile of galantamine in VaD or mixed dementia patients.

        The study population consisted of 459 patients previously randomised to receive galantamine 24 mg/d or placebo in a double-blind study phase. Patients in both treatment groups received open label treatment (164 placebo/galantamine, 295 galantamine/galantamine) for 6 months.

        The primary efficacy measure was change in cognition, based on scores on the standard11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog/11). Secondary measures included changes in functional ability based on the Disability Assessment for Dementia (DAD), and behaviour based on the Neuropsychiatric Inventory (NPI). Safety and tolerability were also monitored.

        Approximately 81.5% of patients completed the study (120 placebo/galantamine, 254 galantamine/galantamine). Principle reasons for discontinuation included adverse events (32 patients), withdrawn consent (6 patients), death unrelated to treatment (2 patients), and non-compliance (2 patients).

        In the previous 6-month double-blind study phase, patients receiving placebo worsened significantly from baseline in ADAS-cog/11 scores while patients receiving galantamine improved significantly. At the end of the open-label extension (study month 12), both treatment groups improved from baseline in ADAS-cog/11 scores (-0.3 point placebo/galantamine [95% CI, -1.64 to 1.06], -0.9 point galantamine/galantamine [95% CI, -1.73 to 0.03]).

        Alternatively, DAD scores suggested that functional ability at month 12 had deteriorated from baseline and month 6 in both treatment groups, although greater change occurred in patients receiving placebo in the double-blind phase.

        Total NPI scores at month 12 did not differ significantly from baseline in either treatment group, indicating that galantamine treatment prevented new behavioural symptoms.

        Overall, researchers concluded that cognitive function and behavior were maintained for 12 months with galantamine, and significant benefits were seen in terms of functional ability. The majority of patients benefited from galantamine treatment, regardless of diagnosis (VaD or mixed dementia).
        Clin Ther 2003 Jun;25:6:1765-82. "An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send